title: Aluminum speciation studies in biological fluids. Part 6. Quantitative investigation of aluminum(III)-tartrate complex equilibria and their potential implications for aluminum metabolism and toxicity.
abstract: Recent epidemiological studies have confirmed the existence of a correlation between aluminum level in low-silica drinking water and prevalence of Alzheimer's disease. Also, oral aluminum-based phosphate binders and antacids may induce acute aluminum toxicity. Whatever the source of the metal ingested, its bioavailability is a function of the chemical forms under which it occurs in the gastrointestinal tract, i.e. of the ligands with which the Al3+ ion may associate. Dietary acids in particular can favor the bioavailability of aluminum in different ways: by increasing its solubility, by complexing it into neutral species, and/or by acting indirectly on its absorption process. Among these, tartaric acid is commonly found in fruits and in industrial foods and drinks, and may therefore be ingested together with environmental or/and therapeutic aluminum. The present work examines its potential influence on aluminum bioavailability. Firstly, Al(III)-tartrate complex formation constants have been determined under physiological conditions (37 degrees C, 0.15 M NaCl). Then these constants have been used to simulate the influence of tartrate on aluminum speciation in different gastrointestinal situations in which phosphate was also taken into account. Under normal conditions of aluminum contamination, tartrate is expected to keep the metal soluble throughout the whole pH range of the small intestine, which is likely to enhance its bioavailability. Even at low concentrations, tartrate also gives rise to two neutral complexes that span over the 1.5-7.5 pH interval, a phenomenon that is aggravated by increased aluminum levels as may result from aluminum hydroxide therapy. The co-occurrence of dietary phosphate reduces the fraction of aluminum neutralized by tartrate under normal conditions, but this effect quickly decreases with increasing aluminum doses. Even the therapeutic use of aluminum phosphate is not expected to be totally safe in the presence of tartaric acid. As plasma simulations show that no aluminum mobilization can be expected from tartrate that could enhance aluminum excretion, avoiding ingestion of tartaric acid during any form of aluminum-based therapy appears advisable.
authors.affiliation: Equipe de Chimie Bioinorganique Médicale, ICMPS-CNRS FR1744, Université Paul Sabatier, Toulouse, France.
authors.forename: S
authors.initials: S
authors.lastname: Desroches
authors.forename: S
authors.initials: S
authors.lastname: Daydé
authors.forename: G
authors.initials: G
authors.lastname: Berthon
mesh_terms: D000535:Aluminum / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics*; D001682:Biological Availability; D001769:Blood / Q000378:metabolism; D001826:Body Fluids / Q000378:metabolism; D003198:Computer Simulation; D004064:Digestive System / Q000378:metabolism; D006801:Humans; D013644:Tartrates / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics*
chemical_list: D013644:Tartrates; D000535:Aluminum; C029768:tartaric acid